Post‑Melanoma Surveillance for Women After Complete Excision of Primary Cutaneous Melanoma with Clear Margins

Comprehensive Skin Examination

Perform a full‑body skin inspection, including the scalp, to identify second primary melanomas or metastatic lesions in all patients with an isolated primary melanoma. 1
This examination is a standard recommendation for every individual with a solitary cutaneous melanoma, regardless of tumor location. 2

Palpate all regional lymph node basins (e.g., axillary and, when appropriate, cervical nodes for back lesions) during follow‑up visits. 1
Ultrasound of superficial nodes should be reserved for cases where clinical palpation is equivocal; it is not a routine study for all patients. 2

No additional imaging (CT, MRI, PET) is required for patients with clear surgical margins and no clinically detectable nodal disease. 1
Routine imaging is discouraged for stage I–IIA melanoma with clear margins and absent palpable nodes because it adds cost and false‑positive findings without improving survival. 2

A gynecologic consultation is not indicated solely on the basis of a cutaneous melanoma of the back; referral should occur only if specific gynecologic symptoms or findings arise. 1
Referral becomes appropriate when regional nodal involvement is identified and further evaluation of pelvic organs is needed, typically after appropriate imaging. 2

Sentinel lymph node biopsy may be considered for tumors ≥0.8 mm thickness or those that are ulcerated, as part of surgical staging rather than routine imaging. 3

When nodal metastasis is present, systematic search for distant disease is justified to guide therapy. 1
Approximately 10 % of patients with nodal involvement have asymptomatic distant metastases at the time of diagnosis. 1
Abdominal, thoracic, and cerebral CT scans are the imaging modalities most useful for detecting distant metastatic spread. 2

Always record tumor thickness (Breslow depth), ulceration status, and Clark level from the pathology report, as these parameters determine surveillance intensity and eligibility for adjuvant therapy. 3
Do not omit a full‑body skin examination; failure to detect a second primary melanoma is a preventable error. 1
Avoid ordering routine cross‑sectional imaging for early‑stage disease with clear margins and no palpable nodes, as it does not confer a survival advantage. 2

State explicitly that a skin examination was performed and record the result as “normal,” “unremarkable,” or “no abnormalities detected.” 4
Use standardized phrasing such as “skin: normal” or “skin: no rashes, lesions, or masses noted.” 4

For a full‑body or complete skin examination, document that all skin surfaces (including scalp when appropriate) were inspected. 5
Indicate whether the exam was focused on a specific area or complete covering the entire body. 5

In patients at high risk (e.g., receiving immunotherapy, living with HIV, or under melanoma surveillance), explicitly note the absence of concerning findings such as suspicious pigmented lesions, seborrheic dermatitis, Kaposi sarcoma, or fungal infections. 5
Also record the absence of rash, blistering, erythema, bullae, erosions, or immune‑related adverse events in these high‑risk groups. 6

Examine and document mucous membranes when the clinical context warrants it. [5][6]
When caring for patients with cancer or on systemic therapies, state that no treatment‑related skin changes were observed. 7

Never omit documentation of the skin examination; failure to do so creates medicolegal risk. 5
Avoid overly detailed descriptions of normal skin characteristics (e.g., “skin is smooth, soft, warm, dry, intact with normal turgor”) to reduce documentation burden. 4
Maintain consistent terminology across all examinations to ensure clarity and uniformity. 4